These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30133453)

  • 1. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study.
    Avong YK; Jatau B; Gurumnaan R; Danat N; Okuma J; Usman I; Mordi D; Ukpabi B; Kayode GA; Dutt S; El-Tayeb O; Afolabi B; Ambrose I; Agbaji O; Osakwe A; Ibrahim A; Ogar C; Nosiri H; Avong EB; Adekanmbi V; Uthman O; Abimiku A; Oni YO; Mensah CO; Dakum P; Mberu KE; Ogundahunsi OAT
    PLoS One; 2018; 13(8):e0200810. PubMed ID: 30133453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria.
    Adisa R; Omitogun TI
    BMC Health Serv Res; 2019 Dec; 19(1):926. PubMed ID: 31796034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Awareness, knowledge, attitude, and practice of adverse drug reaction reporting among health workers in primary health centres participating in seasonal malaria chemoprevention campaign in Nigeria in 2022: a cross-sectional survey.
    Rotimi K; Fagbemi B; Omole G; Biambo AA; Ibinaiye T; Iwegbu A; Ogunmola O; Oguoma C; Oresanya O
    BMC Health Serv Res; 2024 Aug; 24(1):952. PubMed ID: 39164692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
    Masuka JT; Khoza S
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
    Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
    S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience.
    Kalaiselvan V; Shukla S; Arora S; Shrivastava TP; Raghuvanshi RS
    Front Public Health; 2022; 10():930696. PubMed ID: 36062131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening the Bolivian pharmacovigilance system: New surveillance strategies to improve care for Chagas disease and tuberculosis.
    Cortes-Serra N; Saravia R; Grágeda RM; Apaza A; González JA; Ríos B; Gascón J; Torrico F; Pinazo MJ
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008370. PubMed ID: 32956348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria.
    Adisa R; Adeniyi OR; Fakeye TO
    Int J Clin Pharm; 2019 Aug; 41(4):1062-1073. PubMed ID: 31140162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions, practices and barriers to reporting of adverse drug reactions among HIV infected patients and their doctors in 3 public sector hospitals of the Ethekwini Metropolitan, Kwa-Zulu Natal: a cross sectional and retrospective analysis.
    Zondi S; Naidoo P
    BMC Health Serv Res; 2022 Aug; 22(1):1054. PubMed ID: 35982442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis.
    Terblanche A; Meyer JC; Godman B; Summers RS
    Hosp Pract (1995); 2017 Dec; 45(5):238-245. PubMed ID: 28914115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
    Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
    Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda.
    Katusiime B; Semakula D; Lubinga SJ
    Afr Health Sci; 2015 Dec; 15(4):1308-17. PubMed ID: 26958036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
    Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
    Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance amongst patent medicine vendors (PMVs) in Ekiti state, Nigeria.
    Awodele O; Adeniran A; Awodele DF
    Int J Risk Saf Med; 2012; 24(2):65-72. PubMed ID: 22751188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.